[Retracted] Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
Table 1
Patient characteristics at the time of NSCLC diagnosis.
Patient characteristics
Osimertinib treated with T790M, n = 28 (%)
Osimertinib treated without T790M, n = 16 (%)
First-/second-generation EGFR-TKI, n = 34 (%)
value
Age, year (range)
61 (32–78)
52 (28–68)
63 (41–73)
0.322
Median time to LM, months (95% CI)
15.0 (6.0–25.0)
12.5 (6.0–24.0)
3.5 (0.0–12.0)
0.566
Sex
0.408
Male
12 (42.9)
10 (62.5)
15 (44.1)
Female
16 (57.1)
6 (37.5)
19 (55.9)
Smoking status
0.083
Current or former
8 (28.6)
7 (43.8)
5 (14.7)
Never
20 (71.4)
9 (56.2)
29 (85.3)
Number of metastatic sites, n (%)
0.567
≤2
6 (24.0)
5 (35.7)
11 (36.7)
≥3
19 (76.0)
9 (64.3)
19 (63.3)
Histology
0.415
Adenocarcinoma
27 (96.4)
16 (100.0)
34 (100.0)
Adenosquamous carcinoma
1 (3.6)
0
0
ECOG PS score at LM Dx
0.097
0–1
9 (32.1)
6 (37.5)
8 (23.5)
2–3
18 (64.3)
7 (43.8)
18 (52.9)
4
1 (3.6)
3 (18.8)
8 (23.5)
EGFR mutation
0.707
Exon 19
14 (50.0)
11 (68.8)
17 (50.0)
Exon 21
12 (42.9)
4 (25.0)
17 (50.0)
Exon 18
2 (7.1)
1 (6.2)
0
Note. NSCLC: non-small-cell lung cancer, ECOG PS: Eastern Cooperative Oncology Group performance status, and EGFR: epidermal growth factor receptor.
